KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Cash & Equivalents (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Cash & Equivalents for 13 consecutive years, with $104.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash & Equivalents rose 19.28% to $104.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $104.5 million, a 19.28% increase, with the full-year FY2024 number at $142.7 million, down 3.99% from a year prior.
  • Cash & Equivalents was $104.5 million for Q3 2025 at Xenon Pharmaceuticals, down from $624.8 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $624.8 million in Q2 2025 to a low of $57.2 million in Q4 2022.
  • A 5-year average of $144.0 million and a median of $103.5 million in 2022 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: soared 481.52% in 2021, then tumbled 82.55% in 2023.
  • Xenon Pharmaceuticals' Cash & Equivalents stood at $175.7 million in 2021, then tumbled by 67.42% to $57.2 million in 2022, then skyrocketed by 159.67% to $148.6 million in 2023, then dropped by 3.99% to $142.7 million in 2024, then decreased by 26.77% to $104.5 million in 2025.
  • Per Business Quant, the three most recent readings for XENE's Cash & Equivalents are $104.5 million (Q3 2025), $624.8 million (Q2 2025), and $116.7 million (Q1 2025).